Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Milde-Langosch

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Virchows Archiv : an International Journal of Pathology|April 1, 1996
Comparison of benign and malignant endometrial lesions for their p53 state, using immunohistochemistry and temperature-gradient gel electrophoresisL Riethdorf, C Begemann, S Riethdorf, et al.
Hormone Research|February 22, 2001
Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factorsA M Bamberger, K Milde-Langosch, H M Schulte, et al.
Der Pathologe|September 24, 2008
[Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy]E Kilic, K Milde-Langosch, V Müller, et al.
Acta Cytologica|September 1, 1994
Polymerase chain reaction-assisted evaluation of low and high grade squamous intraepithelial lesion cytology and reappraisal of the Bethesda SystemC Kühler-Obbarius, K Milde-Langosch, T Löning, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 19, 2015
Prognostic impact of chondroitin-4-sulfotransferase CHST11 in ovarian cancerL Oliveira-Ferrer, A Heßling, F Trillsch, et al.
Breast Cancer Research and Treatment|August 24, 2001
Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotypeK Milde-Langosch, A M Bamberger, G Rieck, et al.
Virchows Archiv : an International Journal of Pathology|August 14, 2001
Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomasK Milde-Langosch, S Riethdorf, A Kraus-Pöppinghaus, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|March 2, 2002
PTEN expression in breast and endometrial cancer: correlations with steroid hormone receptor statusH Kappes, C Goemann, A M Bamberger, et al.
International Journal of Cancer|August 5, 2000
Expression of cell cycle-regulatory proteins rb, p16/MTS1, p27/KIP1, p21/WAF1, cyclin D1 and cyclin E in breast cancer: correlations with expression of activating protein-1 family membersK Milde-Langosch, A M Bamberger, C Methner, et al.
Journal of Cancer Research and Clinical Oncology|September 26, 2001
Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulatorsA M Bamberger, K Milde-Langosch, E Rössing, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Virchows Archiv : an International Journal of Pathology|April 1, 1996
Comparison of benign and malignant endometrial lesions for their p53 state, using immunohistochemistry and temperature-gradient gel electrophoresisL Riethdorf, C Begemann, S Riethdorf, et al.
Hormone Research|February 22, 2001
Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factorsA M Bamberger, K Milde-Langosch, H M Schulte, et al.
Der Pathologe|September 24, 2008
[Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy]E Kilic, K Milde-Langosch, V Müller, et al.
Acta Cytologica|September 1, 1994
Polymerase chain reaction-assisted evaluation of low and high grade squamous intraepithelial lesion cytology and reappraisal of the Bethesda SystemC Kühler-Obbarius, K Milde-Langosch, T Löning, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 19, 2015
Prognostic impact of chondroitin-4-sulfotransferase CHST11 in ovarian cancerL Oliveira-Ferrer, A Heßling, F Trillsch, et al.
Breast Cancer Research and Treatment|August 24, 2001
Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotypeK Milde-Langosch, A M Bamberger, G Rieck, et al.
Virchows Archiv : an International Journal of Pathology|August 14, 2001
Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomasK Milde-Langosch, S Riethdorf, A Kraus-Pöppinghaus, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|March 2, 2002
PTEN expression in breast and endometrial cancer: correlations with steroid hormone receptor statusH Kappes, C Goemann, A M Bamberger, et al.
International Journal of Cancer|August 5, 2000
Expression of cell cycle-regulatory proteins rb, p16/MTS1, p27/KIP1, p21/WAF1, cyclin D1 and cyclin E in breast cancer: correlations with expression of activating protein-1 family membersK Milde-Langosch, A M Bamberger, C Methner, et al.
Journal of Cancer Research and Clinical Oncology|September 26, 2001
Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulatorsA M Bamberger, K Milde-Langosch, E Rössing, et al.
Pageof 5